Gene Therapy in Oncology Market New Research Study Report with Size, Share, Trends, Emerging Applications, Opportunities and Worldwide Analysis with…
Posted: November 27, 2020 at 1:49 pm
The report provides revenue of the global Gene Therapy in Oncology market for the period 20162026, considering 2019 as the base year and 2026 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global market during the forecast period. The global Gene Therapy in Oncology market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2020 to 2026.
With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.
Due to the high success rate during the preclinical and clinical trial, cancer gene therapy is gaining popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the Gene Therapy in Oncology market across the globe.
Request Coronavirus Impact Analysis on This [emailprotected] https://www.qyresearchmedical.com/sample/57077
A comprehensive estimate on the Gene Therapy in Oncology market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of Gene Therapy in Oncology during the forecast period. Price point comparison by region with global average price is also considered in the study.
It is pertinent to consider that in a volatile global economy, we havent just conducted Gene Therapy in Oncology market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
Download Full Report https://www.qyresearchmedical.com/report/checkout/57077/3500
Drivers and Restraints
This section covers the various factors driving the global Advanced Driver Assistance Systems (ADAS) market. To understand the growth of the market it is important to analyze the various drivers present the market. It provides data by value and volume of different regions and their respective manufacturers. This data will elaborate on the market share occupied by them, predict their revenue concerning strategies, and how they will grow in the future. After explaining the drivers, the report further evaluates the new opportunities and current trends in the market.
Market restraints are factors hampering market growth. Studying these factors is equally pivotal as they help a reader need understand the weaknesses of the market.
Market Segmentation:
The report is divided into major categories comprising product, application, regions and others. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Every segment is studied thoroughly in order to offer a better picture to the buyers and stakeholders to benefit from. Information like highest prevailing product, highly demanded product by the application segment and end users are rightly mentioned in the Gene Therapy in Oncology report.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global Gene Therapy in Oncology market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global Gene Therapy in Oncology market.
Gene Therapy in Oncology Breakdown Data by TypeEx VivoIn VivoGene Therapy in Oncology Breakdown Data by ApplicationHospitalsDiagnostics CentersResearch Institutes
In this study, the years considered to estimate the market size of Gene Therapy in Oncology are as follows:
Major Players Covered in this Report
The updated market research report on Gene Therapy in Oncology market allows the buyers and manufacturers to stay updated with the current market trends, ongoing happenings, and a clear picture on the market scenario. List of key players included in the research report will help the market vendors to know their market position and plan more operational strategies to gain topmost position among other players. The report offers crucial company information on each market player, such as company profile, financial information, and recently adopted growth strategies. This will help other existing players and the new entrants to plan strategies and establish their presence in the market.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
Bristol-Myers SquibbCold GenesysAdvantageneAmgenAstraZenecaBio-Path HoldingsCRISPR TherapeuticsEditas MedicineGeron CorpIdera PharmaceuticalsIntellia TherapeuticsJohnson & JohnsonMarsala BiotechMerckMologen AGOncolytics BiotechOncosecOncotelicShenzhen SiBiono GeneTechSillajen BiotherapeuticsTocagenUniQureZiopharm Oncology
Regional Insights:
The Gene Therapy in Oncology market is segmented as North America, South America, Europe, Asia Pacific, and Middle East and Africa. Researchers have thoroughly studied about the historical market. With extensive research, experts have offered details on the current and the forecast demand made by these regions. The Gene Therapy in Oncology report also includes highlights on the prevailing product demanded by end users and end customers for better understanding of product demand by producers. This will help the producers and the marketing executives to plan their production quantity and plan effective marketing strategies to more buyers. Businesses can hence, increase their product portfolio and expand their global presence. Gene Therapy in Oncology market research report further offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. This will again help the manufacturers to increase their customers and emerge as leaders in the near future.
TABLE OF CONTENT
1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Gene Therapy in Oncology Revenue1.4 Market Analysis by Type1.4.1 Global Gene Therapy in Oncology Market Size Growth Rate by Type: 2020 VS 20261.4.2 Ex Vivo1.4.3 In Vivo1.5 Market by Application1.5.1 Global Gene Therapy in Oncology Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Diagnostics Centers1.5.4 Research Institutes1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy in Oncology Industry Impact1.6.1 How the Covid-19 is Affecting the Gene Therapy in Oncology Industry1.6.1.1 Gene Therapy in Oncology Business Impact Assessment Covid-191.6.1.2 Supply Chain Challenges1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Gene Therapy in Oncology Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-191.6.3.1 Government Measures to Combat Covid-19 Impact1.6.3.2 Proposal for Gene Therapy in Oncology Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered
2 Global Growth Trends by Regions2.1 Gene Therapy in Oncology Market Perspective (2015-2026)2.2 Gene Therapy in Oncology Growth Trends by Regions2.2.1 Gene Therapy in Oncology Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Gene Therapy in Oncology Historic Market Share by Regions (2015-2020)2.2.3 Gene Therapy in Oncology Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Gene Therapy in Oncology Market Growth Strategy2.3.6 Primary Interviews with Key Gene Therapy in Oncology Players (Opinion Leaders)
3 Competition Landscape by Key Players3.1 Global Top Gene Therapy in Oncology Players by Market Size3.1.1 Global Top Gene Therapy in Oncology Players by Revenue (2015-2020)3.1.2 Global Gene Therapy in Oncology Revenue Market Share by Players (2015-2020)3.1.3 Global Gene Therapy in Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Gene Therapy in Oncology Market Concentration Ratio3.2.1 Global Gene Therapy in Oncology Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy in Oncology Revenue in 20193.3 Gene Therapy in Oncology Key Players Head office and Area Served3.4 Key Players Gene Therapy in Oncology Product Solution and Service3.5 Date of Enter into Gene Therapy in Oncology Market3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)4.1 Global Gene Therapy in Oncology Historic Market Size by Type (2015-2020)4.2 Global Gene Therapy in Oncology Forecasted Market Size by Type (2021-2026)
5 Gene Therapy in Oncology Breakdown Data by Application (2015-2026)5.1 Global Gene Therapy in Oncology Market Size by Application (2015-2020)5.2 Global Gene Therapy in Oncology Forecasted Market Size by Application (2021-2026)
6 North America6.1 North America Gene Therapy in Oncology Market Size (2015-2020)6.2 Gene Therapy in Oncology Key Players in North America (2019-2020)6.3 North America Gene Therapy in Oncology Market Size by Type (2015-2020)6.4 North America Gene Therapy in Oncology Market Size by Application (2015-2020)
7 Europe7.1 Europe Gene Therapy in Oncology Market Size (2015-2020)7.2 Gene Therapy in Oncology Key Players in Europe (2019-2020)7.3 Europe Gene Therapy in Oncology Market Size by Type (2015-2020)7.4 Europe Gene Therapy in Oncology Market Size by Application (2015-2020)
8 China8.1 China Gene Therapy in Oncology Market Size (2015-2020)8.2 Gene Therapy in Oncology Key Players in China (2019-2020)8.3 China Gene Therapy in Oncology Market Size by Type (2015-2020)8.4 China Gene Therapy in Oncology Market Size by Application (2015-2020)
9 Japan9.1 Japan Gene Therapy in Oncology Market Size (2015-2020)9.2 Gene Therapy in Oncology Key Players in Japan (2019-2020)9.3 Japan Gene Therapy in Oncology Market Size by Type (2015-2020)9.4 Japan Gene Therapy in Oncology Market Size by Application (2015-2020)
10 Southeast Asia10.1 Southeast Asia Gene Therapy in Oncology Market Size (2015-2020)10.2 Gene Therapy in Oncology Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Gene Therapy in Oncology Market Size by Type (2015-2020)10.4 Southeast Asia Gene Therapy in Oncology Market Size by Application (2015-2020)
11 India11.1 India Gene Therapy in Oncology Market Size (2015-2020)11.2 Gene Therapy in Oncology Key Players in India (2019-2020)11.3 India Gene Therapy in Oncology Market Size by Type (2015-2020)11.4 India Gene Therapy in Oncology Market Size by Application (2015-2020)
12 Central & South America12.1 Central & South America Gene Therapy in Oncology Market Size (2015-2020)12.2 Gene Therapy in Oncology Key Players in Central & South America (2019-2020)12.3 Central & South America Gene Therapy in Oncology Market Size by Type (2015-2020)12.4 Central & South America Gene Therapy in Oncology Market Size by Application (2015-2020)
13 Key Players Profiles13.1 Bristol-Myers Squibb13.1.1 Bristol-Myers Squibb Company Details13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue13.1.3 Bristol-Myers Squibb Gene Therapy in Oncology Introduction13.1.4 Bristol-Myers Squibb Revenue in Gene Therapy in Oncology Business (2015-2020))13.1.5 Bristol-Myers Squibb Recent Development13.2 Cold Genesys13.2.1 Cold Genesys Company Details13.2.2 Cold Genesys Business Overview and Its Total Revenue13.2.3 Cold Genesys Gene Therapy in Oncology Introduction13.2.4 Cold Genesys Revenue in Gene Therapy in Oncology Business (2015-2020)13.2.5 Cold Genesys Recent Development13.3 Advantagene13.3.1 Advantagene Company Details13.3.2 Advantagene Business Overview and Its Total Revenue13.3.3 Advantagene Gene Therapy in Oncology Introduction13.3.4 Advantagene Revenue in Gene Therapy in Oncology Business (2015-2020)13.3.5 Advantagene Recent Development13.4 Amgen13.4.1 Amgen Company Details13.4.2 Amgen Business Overview and Its Total Revenue13.4.3 Amgen Gene Therapy in Oncology Introduction13.4.4 Amgen Revenue in Gene Therapy in Oncology Business (2015-2020)13.4.5 Amgen Recent Development13.5 AstraZeneca13.5.1 AstraZeneca Company Details13.5.2 AstraZeneca Business Overview and Its Total Revenue13.5.3 AstraZeneca Gene Therapy in Oncology Introduction13.5.4 AstraZeneca Revenue in Gene Therapy in Oncology Business (2015-2020)13.5.5 AstraZeneca Recent Development13.6 Bio-Path Holdings13.6.1 Bio-Path Holdings Company Details13.6.2 Bio-Path Holdings Business Overview and Its Total Revenue13.6.3 Bio-Path Holdings Gene Therapy in Oncology Introduction13.6.4 Bio-Path Holdings Revenue in Gene Therapy in Oncology Business (2015-2020)13.6.5 Bio-Path Holdings Recent Development13.7 CRISPR Therapeutics13.7.1 CRISPR Therapeutics Company Details13.7.2 CRISPR Therapeutics Business Overview and Its Total Revenue13.7.3 CRISPR Therapeutics Gene Therapy in Oncology Introduction13.7.4 CRISPR Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)13.7.5 CRISPR Therapeutics Recent Development13.8 Editas Medicine13.8.1 Editas Medicine Company Details13.8.2 Editas Medicine Business Overview and Its Total Revenue13.8.3 Editas Medicine Gene Therapy in Oncology Introduction13.8.4 Editas Medicine Revenue in Gene Therapy in Oncology Business (2015-2020)13.8.5 Editas Medicine Recent Development13.9 Geron Corp13.9.1 Geron Corp Company Details13.9.2 Geron Corp Business Overview and Its Total Revenue13.9.3 Geron Corp Gene Therapy in Oncology Introduction13.9.4 Geron Corp Revenue in Gene Therapy in Oncology Business (2015-2020)13.9.5 Geron Corp Recent Development13.10 Idera Pharmaceuticals13.10.1 Idera Pharmaceuticals Company Details13.10.2 Idera Pharmaceuticals Business Overview and Its Total Revenue13.10.3 Idera Pharmaceuticals Gene Therapy in Oncology Introduction13.10.4 Idera Pharmaceuticals Revenue in Gene Therapy in Oncology Business (2015-2020)13.10.5 Idera Pharmaceuticals Recent Development13.11 Intellia Therapeutics10.11.1 Intellia Therapeutics Company Details10.11.2 Intellia Therapeutics Business Overview and Its Total Revenue10.11.3 Intellia Therapeutics Gene Therapy in Oncology Introduction10.11.4 Intellia Therapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)10.11.5 Intellia Therapeutics Recent Development13.12 Johnson & Johnson10.12.1 Johnson & Johnson Company Details10.12.2 Johnson & Johnson Business Overview and Its Total Revenue10.12.3 Johnson & Johnson Gene Therapy in Oncology Introduction10.12.4 Johnson & Johnson Revenue in Gene Therapy in Oncology Business (2015-2020)10.12.5 Johnson & Johnson Recent Development13.13 Marsala Biotech10.13.1 Marsala Biotech Company Details10.13.2 Marsala Biotech Business Overview and Its Total Revenue10.13.3 Marsala Biotech Gene Therapy in Oncology Introduction10.13.4 Marsala Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)10.13.5 Marsala Biotech Recent Development13.14 Merck10.14.1 Merck Company Details10.14.2 Merck Business Overview and Its Total Revenue10.14.3 Merck Gene Therapy in Oncology Introduction10.14.4 Merck Revenue in Gene Therapy in Oncology Business (2015-2020)10.14.5 Merck Recent Development13.15 Mologen AG10.15.1 Mologen AG Company Details10.15.2 Mologen AG Business Overview and Its Total Revenue10.15.3 Mologen AG Gene Therapy in Oncology Introduction10.15.4 Mologen AG Revenue in Gene Therapy in Oncology Business (2015-2020)10.15.5 Mologen AG Recent Development13.16 Oncolytics Biotech10.16.1 Oncolytics Biotech Company Details10.16.2 Oncolytics Biotech Business Overview and Its Total Revenue10.16.3 Oncolytics Biotech Gene Therapy in Oncology Introduction10.16.4 Oncolytics Biotech Revenue in Gene Therapy in Oncology Business (2015-2020)10.16.5 Oncolytics Biotech Recent Development13.17 Oncosec10.17.1 Oncosec Company Details10.17.2 Oncosec Business Overview and Its Total Revenue10.17.3 Oncosec Gene Therapy in Oncology Introduction10.17.4 Oncosec Revenue in Gene Therapy in Oncology Business (2015-2020)10.17.5 Oncosec Recent Development13.18 Oncotelic10.18.1 Oncotelic Company Details10.18.2 Oncotelic Business Overview and Its Total Revenue10.18.3 Oncotelic Gene Therapy in Oncology Introduction10.18.4 Oncotelic Revenue in Gene Therapy in Oncology Business (2015-2020)10.18.5 Oncotelic Recent Development13.19 Shenzhen SiBiono GeneTech10.19.1 Shenzhen SiBiono GeneTech Company Details10.19.2 Shenzhen SiBiono GeneTech Business Overview and Its Total Revenue10.19.3 Shenzhen SiBiono GeneTech Gene Therapy in Oncology Introduction10.19.4 Shenzhen SiBiono GeneTech Revenue in Gene Therapy in Oncology Business (2015-2020)10.19.5 Shenzhen SiBiono GeneTech Recent Development13.20 Sillajen Biotherapeutics10.20.1 Sillajen Biotherapeutics Company Details10.20.2 Sillajen Biotherapeutics Business Overview and Its Total Revenue10.20.3 Sillajen Biotherapeutics Gene Therapy in Oncology Introduction10.20.4 Sillajen Biotherapeutics Revenue in Gene Therapy in Oncology Business (2015-2020)10.20.5 Sillajen Biotherapeutics Recent Development13.21 Tocagen10.21.1 Tocagen Company Details10.21.2 Tocagen Business Overview and Its Total Revenue10.21.3 Tocagen Gene Therapy in Oncology Introduction10.21.4 Tocagen Revenue in Gene Therapy in Oncology Business (2015-2020)10.21.5 Tocagen Recent Development13.22 UniQure10.22.1 UniQure Company Details10.22.2 UniQure Business Overview and Its Total Revenue10.22.3 UniQure Gene Therapy in Oncology Introduction10.22.4 UniQure Revenue in Gene Therapy in Oncology Business (2015-2020)10.22.5 UniQure Recent Development13.23 Ziopharm Oncology10.23.1 Ziopharm Oncology Company Details10.23.2 Ziopharm Oncology Business Overview and Its Total Revenue10.23.3 Ziopharm Oncology Gene Therapy in Oncology Introduction10.23.4 Ziopharm Oncology Revenue in Gene Therapy in Oncology Business (2015-2020)10.23.5 Ziopharm Oncology Recent Development
14 Analysts Viewpoints/Conclusions
15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details
Download Full Report https://www.qyresearchmedical.com/report/checkout/57077/3500
Contact Us:
QYResearch Medical
URL http://www.qyresearchmedical.com/
Mailing Address : Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Any Assistance, Email [emailprotected]
- This Pitt program is leveling up the gene therapy workforce in Pittsburgh - University of Pittsburgh - March 12th, 2024
- Opinion | Banning Gain-of-Function Research Would Do Far More Harm Than Good - Medpage Today - March 12th, 2024
- The Biggest Challenges Facing Broader Adoption of Novel Cell and Gene Therapies - Pharmaceutical Executive - March 12th, 2024
- Research and development areas of focus - Bristol Myers Squibb - March 4th, 2024
- Overcoming the challenges of gene therapy - Drug Discovery News - March 4th, 2024
- Breakthrough Gene Therapy for LHON: Vision Restoration in Focus at Medical Conference - BNN Breaking - March 4th, 2024
- Revolutionizing Healthcare: Global Gene Therapy Market Surges to US$ 3.44 Billion by 2022 As Revealed In Ne... - WhaTech - March 4th, 2024
- Looking to the future of clinical trials: Gene therapy, precision medicine, and the ongoing quest for rare disease solutions - pharmaphorum - March 4th, 2024
- Complement system response to AAV vector gene therapy - EurekAlert - February 23rd, 2024
- 10 gene therapy companies you should know about - Labiotech.eu - February 23rd, 2024
- Fetal surgery expert Tippi MacKenzie shifts to in-utero gene therapy - STAT - February 23rd, 2024
- Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age ... - Business Wire - February 23rd, 2024
- Combatting HIV using gene therapy - Drug Target Review - February 23rd, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 23rd, 2024
- Global Advanced Therapy Medicinal Products CDMO Market Analysis Report 2024-2030: : Increasing Investment and ... - Yahoo Finance UK - February 23rd, 2024
- 2023 gene therapy research STAR Grant winners announced - Pacific Biosciences - February 13th, 2024
- Lifetime Cost of DEB Gene Therapy Could Be $15-$22 Million - Medscape - February 13th, 2024
- 5 Things Youll Learn in Frederick Community Colleges New Cell and Gene Therapy Essentials Certificate ... - BioBuzz - February 13th, 2024
- Regenxbios investigational gene therapy shows promise in Hunter syndrome - PMLiVE - February 13th, 2024
- Topical Gene Therapy Effective in Treating Debilitating Eye Condition - InventUM - University of Miami - February 13th, 2024
- Bayer Says First Patient Randomized In Askbio Phase II Gene Therapy Trial - XM - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Realistic Expectations, Limitations With Gene Therapy for Parkinson Disease: Ignacio Mata, PhD - Neurology Live - February 5th, 2024
- Gene-Based Therapy May Slow Development of Life-Threatening Heart Condition - NYU Langone Health - February 5th, 2024
- After Promising Early Efficacy, Eli Lilly Eager to Study Hearing Loss Gene Therapy in More Children - precisionmedicineonline.com - February 5th, 2024
- Gene therapy hailed as medical magic wand for hereditary swelling disorder - The Guardian - February 5th, 2024
- France Approves Gene Therapy Clinical Trial to Treat Hearing Loss in Children - The Hearing Review - February 5th, 2024
- Early Trial Success for Inherited Deafness Gene-Therapy - RegMedNet - February 5th, 2024
- Can gene therapy be the key to restoring hearing loss? - Labiotech.eu - February 5th, 2024
- Jaguar Gene Therapy Announces FDA Clearance of IND to Study JAG201 in a Genetic Form of Autism Spectrum ... - Business Wire - February 5th, 2024
- FDA inspection clears Abeona's gene therapy BLA By Investing.com - Investing.com - February 5th, 2024
- Hearing Restored in Deaf Children in Gene Therapy Clinical Trial - Securities.io - February 5th, 2024
- Experimental gene therapy allows kids with inherited deafness to hear - The Associated Press - January 28th, 2024
- Children with genetic deafness have hearing restored with gene therapy: Study - ABC News - January 28th, 2024
- Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at ... - Investors | Eli Lilly and... - January 28th, 2024
- UChicago Medicine among the first in the country to offer newly approved sickle cell gene therapies - UChicago Medicine - January 28th, 2024
- Gene Therapy Allows an 11-Year-Old Boy to Hear for the First Time - The New York Times - January 28th, 2024
- Gene therapy restores hearing in children with hereditary deafness - EurekAlert - January 28th, 2024
- Experimental gene therapy helps treat kids with inherited hearing loss - CBS News - January 28th, 2024
- Children's Hospital of Philadelphia Performs First in U.S. Gene Therapy Procedure to Treat Genetic Hearing Loss - PR Newswire - January 28th, 2024
- Gene Therapy Brings Hearing to Kids With Congenital Deafness - U.S. News & World Report - January 28th, 2024
- Gene Therapy Restores Hearing in Small Trial for Kids With Hereditary Deafness - Technology Networks - January 28th, 2024
- Cell Therapies on Ice: Seven Trends in Cryopreservation To Enable Cell and Gene Therapy Research - Technology Networks - January 28th, 2024
- Gene Therapy Brings Hearing to Kids With Congenital Deafness - HealthDay - January 28th, 2024
- Gene therapies restore hearing in several kids with inherited deafness - Livescience.com - January 28th, 2024
- 11-Year-Old Boy Hears For First Time Ever Thanks To Gene Therapy Breakthrough - IFLScience - January 28th, 2024
- Innovative Gene Therapy Restores Hearing In Deaf Child, Offering Potential Cure - Study Finds - January 28th, 2024
- Sound of Success, Gene Therapy Breakthrough Grants Hearing to Deaf Children in China-Harvard Study - Hoodline - January 28th, 2024
- Perspectives in FTD Research Webinar: Gene Therapy for FTD -- What Do I Need to Know? | AFTD - AFTD - January 20th, 2024
- UK leads the way in cell and gene therapy - Research Professional News - January 20th, 2024
- Charles River's (CRL) New Launch to Boost Gene Therapy Programs - Yahoo Finance - January 20th, 2024
- UK maintains status as an attractive destination for advanced therapy clinical trials - BioPharma-Reporter.com - January 20th, 2024
- Understanding the impact of AI on the advancement of gene therapy development - pharmaphorum - January 20th, 2024
- Gene therapy TSHA-102 delivered to 1st child in REVEAL trial - Rett Syndrome News - January 20th, 2024
- AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032 ... - PR Newswire - January 20th, 2024
- Family pins hopes on gene therapy - The Recorder and Times - January 20th, 2024
- Arbor, 4DMT partner on new gene therapies in ALS, other diseases - ALS News Today - January 11th, 2024
- The year of gene therapy? FDA's Marks calls for solutions to regulatory, manufacturing challenges - BioWorld Online - January 11th, 2024
- Gene Therapy Approvals Expected to Ramp Up in 2024 Amid Manufacturing, Cost Challenges - BioSpace - January 11th, 2024
- Turning On Gene Therapy with the pA Regulator - RegMedNet - January 11th, 2024
- Revolutionizing Healthcare: Gene Therapy Market Projected to Reach USD 46.5 billion by 2030 at a 22. - PharmiWeb.com - January 11th, 2024
- Regeneron CEO Reveals the Game-Changing Potential of Gene Therapy in Biotech! - BioTecNika - January 11th, 2024
- Bayer's AskBio checks off another early win for gene therapy platform with Parkinson's safety data - FierceBiotech - January 11th, 2024
- Are Rare Brain Diseases the Next Commercial Frontier for Gene Therapy? - MedCity News - January 3rd, 2024
- Novartis, Voyager Ink Up-to-$1.3B Expansion of Neuro Gene Therapy Collaboration - Genetic Engineering & Biotechnology News - January 3rd, 2024
- Novel switch turns genes on/off on cue, a promising step toward safer gene therapy - Phys.org - January 3rd, 2024
- Which Therapeutic Areas Experts Think Will Gain Traction In 2024 - Clinical Leader - January 3rd, 2024
- Voyager Therapeutics and Novartis Announce Major Licensing Deal in Gene Therapy Field - Medriva - January 3rd, 2024
- We Are About to Enter the Golden Age of Gene Therapy - Inverse - January 3rd, 2024
- Revolutionizing Gene Therapy: Baylor Researchers Develop RNA-Based Switch for Therapeutic Protein Control - BNN Breaking - January 3rd, 2024
- Casgevy and Lyfgenia: Two Gene Therapies Approved for Sickle Cell Disease - Yale Medicine - December 25th, 2023
- Top story: Family connects with researchers behind Canavan gene therapy - UMass Medical School - December 25th, 2023
- Excision Bio Seeks to Suppress HIV Replication With CRISPR Gene Therapy - AJMC.com Managed Markets Network - December 25th, 2023
- Hemgenix Gene Therapy Shows Long-Term Efficacy, Safety in Hemophilia B Patients - Managed Healthcare Executive - December 25th, 2023
- The missing piece of the puzzle - EUobserver - December 25th, 2023
- Brace yourselves for these trends in clinical research in 2024 - Labiotech.eu - December 25th, 2023
- RegMedNet's 2023 remix: top content of the year - RegMedNet - December 25th, 2023
- BU Researchers Helped Develop the First FDA-Approved Gene Therapies to Treat Sickle Cell Disease - Boston University - December 16th, 2023
- Research discovers that mice possess a natural gene therapy system - Phys.org - December 16th, 2023
- Cell- and gene-therapy hub bound for Lake Success; New York to invest up to $150 million - Newsday - December 16th, 2023